Cilostazol and Pentoxifylline in Reduced Ejection Fraction
Direct Answer
Cilostazol is absolutely contraindicated in patients with heart failure of any severity, including reduced ejection fraction, while pentoxifylline has no such contraindication and may be used cautiously in this population. 1
Cilostazol: Absolute Contraindication
The FDA label explicitly states that cilostazol is contraindicated in patients with congestive heart failure of any severity. 1 This stems from the drug's mechanism as a phosphodiesterase III inhibitor—a class effect demonstrated by oral milrinone, which showed excess mortality in heart failure with reduced ejection fraction patients. 2
Key Points on Cilostazol:
The contraindication applies regardless of heart failure severity (Class I, II, III, or IV), making it unsuitable for any patient with reduced ejection fraction. 1
The 2024 ACC/AHA peripheral artery disease guidelines reinforce this contraindication, noting that while evidence is limited in heart failure with preserved ejection fraction, the concern for class effect with phosphodiesterase III inhibitors mandates avoidance. 2
Recent research (2025) explored cilostazol in HFpEF patients and showed short-term improvements in health status and NT-proBNP, but this does not change the contraindication status, and the study specifically excluded HFrEF patients. 3
The contraindication is based on safety concerns from the phosphodiesterase III inhibitor class, not on direct evidence of harm from cilostazol itself in heart failure populations. 2
Pentoxifylline: No Contraindication
Pentoxifylline has no FDA contraindication for use in patients with reduced ejection fraction. 4 The only FDA-listed contraindications are recent cerebral/retinal hemorrhage and prior intolerance to pentoxifylline or methylxanthines. 4
Evidence Supporting Pentoxifylline Use in HFrEF:
A 2004 randomized controlled trial in patients with ischemic, hypertensive, and idiopathic-dilated cardiomyopathy (mean LVEF ~28%) found pentoxifylline to be neutral—it did not improve left ventricular function, inflammatory cytokines, or symptoms, but importantly showed no harm. 5
A 2015 study in coronary artery bypass patients with LVEF ≤30% demonstrated that preoperative pentoxifylline reduced inflammatory markers (TNF-α and IL-6), improved LVEF, decreased ICU stay, reduced ventilation time, and lowered requirements for inotropic support and blood transfusion. 6
The 2024 ACC/AHA guidelines note that pentoxifylline showed no difference from placebo in maximal walking distance for claudication, with uncertain effectiveness overall, but do not cite safety concerns in heart failure patients. 2
Clinical Implications:
If treating peripheral artery disease in a patient with reduced ejection fraction, pentoxifylline is the only option between these two agents, though its efficacy for claudication is questionable. 2
Pentoxifylline appears safe in HFrEF based on available evidence, with potential anti-inflammatory benefits in specific surgical contexts. 6
The drug is generally well tolerated, with most adverse effects involving the gastrointestinal tract and central nervous system. 7
Common Pitfalls to Avoid:
Do not prescribe cilostazol to any patient with documented heart failure or reduced ejection fraction, regardless of how well-compensated they appear. 1
Do not assume the cilostazol contraindication only applies to severe (Class III-IV) heart failure—it applies to all severities. 1
While pentoxifylline is not contraindicated, recognize its limited efficacy for claudication compared to cilostazol, which creates a therapeutic dilemma in PAD patients with HFrEF. 2, 7